In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- December 2025 — CDMO Opportunities And Threats Report
- The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs
- Single-Use Standards Are Maturing, But The Process Remains King
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Deploying A Vendor Life Cycle Oversight Model
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
AAV Viral Titering Using Nanoplate-Based Digital PCR
Examine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.
-
Fast And Scalable Fc Quantitation In Supernatants
In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.
-
Engineering The Future Of Lipsomal Drug Delivery
Explore our full collection of case studies to discover how liposome technology is transforming drug delivery across a wide range of therapies.
-
A Toolkit For Unraveling Protein Expression Patterns
Learn about a method that utilizes monoclonal antibodies and flow cytometry to analyze the metabolic state of individual immune cells, advancing immune research and immunotherapy.
-
Prevent The Risk Of Cross-Contamination With Microbial Colony Pickers
Explore a microbial colony picker that streamlines lab workflows to ensure rapid and accurate genetic library screening. Key features include UV sanitization, pin washing, and halogen drying, which meets GMP standards.
-
A Transient Cell Line To Produce rAAV With Low-Level hcDNA Encapsidation
Discover the ability of a novel HEK293 suspension cell line for efficient and scalable rAAV production across various serotypes with low encapsidated host cell DNA levels.
-
Optimizing Performance For De-Risked Lentiviral Vector Production
Discover a de-risked, reproducible, and scalable platform for efficient GMP manufacturing of lentiviral vectors that maximizes titers and enriches recovery through upstream and downstream optimization.
-
Performance Of HEKima™ Adherent HEK Cell Medium
Explore the performance of a serum-free medium designed for HEK-293 cells, comparing its efficacy to traditional media for protein expression and cell proliferation.
-
Automated Sampling Of A Four Vessel Parallel CHO Cell Culture
Learn how automated sampling for parallel bioreactors enables continuous, sterile sample collection from CHO cell cultures, maintaining cell density with reduced manual intervention.
-
6 Key Ways Real-World Data Is Accelerating Breast Cancer Therapies
Real-world data (RWD) is increasingly vital for advancing breast cancer research, and leveraging TA datasets allows researchers and clinicians to address pressing challenges.
NEWSLETTER ARCHIVE
- 02.03.26 -- STREAM Edition: Data Governance And Regulations For AI Use In GMP With Peter Baker
- 02.03.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 02.02.26 -- 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
- 01.30.26 -- Reclaiming Control From Your Raw Materials
- 01.29.26 -- Advancing Off-The-Shelf CRISPR CAR-T Therapies With Rachel Haurwitz
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections